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An immunohistochemical study was performed to localize two distinct Ca*+-proteases (low-Ca2+-requiring 
calpain I and high-Ca2+ -requiring calpain II) and their specific inhibitor (calpastatin) in human pancreas 
using the respective monospecific antibodies. Strongly positive staining by anti-calpain I antibody was 
found in pancreatic slets, s@citically in B-cells, whereas the exocrine pancreatic tissue showed essentially 
no positive immunostaining. No such specific staining was found with anti-calpain II antibodies or anti- 
calpastatin antibodies. The results uggest that the Ca 2+-dependent proteolysis n B-cells can be triggered 
by a small rise of the intracellular Ca2+ concentration without serious interference by the ndogenous inhibi- 
tor. 
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1. INTRODUCTION 
Calpain (EC 3.4.22.17) is the collective name for 
Ca2+-dependent cysteine proteinase [11, one of the 
most important intracellular nonlysosomal pro- 
teases found mainly in the cytosolic fraction. Cal- 
pain is known to be widely distributed in mam- 
malian and avian tissues [2-61, but its 
physiological function remains unclear. Two 
forms of calpains are found which differ in 
Ca*+-requirement: calpain I, the low-, and calpain 
II, the high-Ca2+-requiring form. Some immuno- 
cyto- and/or histo-chemical methods had 
previously been applied to study the distribution 
and localization of calpain in the skeletal muscle 
[7,8], but the interpretation of the results was dif- 
ficult due to the cross-reactivity between conven- 
tionally prepared anti-calpain I and calpain II an- 
tibodies [9, lo]. Two-step affinity chromatography 
t To whom correspondence should be addressed 
is required to obtain specific antibodies which can 
discriminate calpain I and II, as described in 
[11,12]. 
Calpain usually coexists with its specific in- 
hibitor, calpastatin, and consequently calpain ac- 
tivity is regulated by calpastatin as well as by Ca2+ 
levels. A specific antibody against this inhibitor 
was successfully obtained as described in our re- 
cent report [13]. 
Here, we have used these monospecific an- 
tibodies for immunohistochemical localization of 
calpain and calpastatin in human pancreas. 
2. MATERIALS AND METHODS 
2.1. Preparation of antigens and antibodies 
Calpain I was purified from porcine 
erythrocytes, calpain II from porcine kidney and 
calpastatin from human erythrocytes as described 
in [13,14]. The respective 83-kDa subunit protein 
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of calpain I, 80-kDa subunit protein of calpain II, 
and 70-kDa calpastatin were extracted from SDS- 
gels after electrophoresis and used to immunize 
rabbits. The IgG fraction was isolated from an- 
tiserum by ammonium sulfate fractionation and 
DEAE-cellulose chromatography. The anti- 
calpain I 83-kDa subunit IgG (anti-calpain I) was 
purified by subjecting the material sequentially to 
calpain I 83-kDa subunit-Sepharose and calpain II 
80-kDa subunit-Sepharose column chromatog- 
raphies. For the anti-calpain II 80-kDa subunit 
IgG (anti-calpain II), the reverse sequence of the 
two columns was used. These chromatographies 
made the final products completely devoid of the 
cross-reaction between the two types of calpains; 
by immunoelectrophoretic blotting analysis only 
the homologous heavy subunit band was recog- 
nized without any immunological cross-reactivity 
to other proteins. The details of these affinity 
chromatographies were previously described 
[ 11,121. The purified anti-calpastatin IgG was 
obtained by affinity chromatography [13]. The 
following antisera against pancreatic hormones 
were used: guinea pig anti-porcine insulin (1: 300, 
Miles, Elkhart, IN); rabbit anti-glucagon (1: 3750, 
JIMRO, Japan); rabbit anti-bovine pancreatic 
polypeptide (1: 800, a gift from Dr Chance, Lilly); 
rabbit anti-somatostatin (1: 3750, JIMRO, Japan). 
2.2. Immunohistochemical staining of human 
pancreas 
Human pancreas was taken at autopsy, fixed in 
10% neutral formalin for 12 h at room 
temperature and embedded in paraffin by routine 
methods. Series of consecutive and non- 
consecutive paraffin sections from the different 
portions of pancreas were immunostained by the 
peroxidase-anti-peroxidase (PAP) method of 
Sternberger et al. [IS]. Briefly, the sections were 
treated with 0.3% Hz02 in methanol for 30 min, to 
block endogenous peroxidase activity and in- 
cubated with normal porcine serum (1: 10, DAKO, 
Copenhagen, Denmark) or normal rabbit serum 
(1: 10, DAKO) for 30 min at room temperature. In 
the next step, sections were incubated overnight at 
4°C with the following antibodies: affinity- 
purified anti-calpain I (10 pg/ml), anti-calpain II 
(28 pg/ml), anti-calpastatin (30 pg/ml), anti- 
insulin (1 : 300), anti-glucagon (1 : 3750), anti- 
somatostatin (1: 3750), and anti-pancreatic 
polypeptide (1: 800). Further incubation with por- 
cine anti-rabbit IgG (1: 20, DAKO) and PAP com- 
plex (soluble complex of horseradish peroxidase 
and rabbit anti-horseradish peroxidase, 1: 80, 
DAKO) was performed for 30 min at 4”C, except 
for insulin staining where the sections were in- 
cubated with peroxidase-labeled rabbit anti-guinea 
pig IgG. Peroxidase staining was developed using 
diaminobenzidine as the substrate in 0.05 M Tris- 
HCl buffer (pH 7.6) with 0.003% H202. The 
following controls were taken: (a) incubation with 
purified anti-calpain I previously absorbed with 
calpain I (320pg/ml anti-calpain I), calpain II 
(640/1g/ml anti-calpain I) and bovine insulin 
(200-400 ag/ml anti-calpain I); (b) incubation 
with homologous non-immune serum. 
Fig.1. PAP staining of human pancreas by anti-calpain I, anti-calpain II and anti-calpastatin i  non-consecutive 
paraffin sections. A, B and C are stainings obtained by anti-calpain I, anti-calpain II, and anti-calpastatin, respectively. 
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3. RESULTS 
The staining patterns obtained with anti-calpain 
I, anti-calpain II and with anti-calpastatin were 
different in human pancreas as shown in fig.1. 
Calpain I showed positive immunoreactive 
material as indicated by the presence of the reac- 
tion product for peroxidase in the islets of 
Langerhans, but no positive staining was seen in 
the exocrine glands (fig.lA). No positive im- 
munostaining was observed for calpain II or 
calpastatin as shown in figs 1B and lC, 
respectively. 
Fig.2A-E shows the staining patterns of an islet 
which contains predominantly B-cells and a signifi- 
cant number of A- and pp-cells. The distribution 
pattern of calpain I-positive cells coincides with 
that of B-cells, as is clear from fig.2A and B. A- 
cells and pp-cells are essentially negative for cal- 
pain I. Fig.ZF-J shows the staining pattern of an 
islet which contains A-, B- and D-cells. Again, the 
distribution pattern of calpain I-positive cells coin- 
cides with that of B-cells: A- and D-cells are essen- 
tially negative for calpain I. Four pancreases, in- 
cluding one from a 7-year-old child, showed essen- 
tially the same staining pattern. From these data, 
it is clear that calpain I is selectively localized in B- 
cells of pancreatic islets. The specific staining with 
anti-calpain I was blocked only by purified calpain 
I (fig.3A), but not by purified calpain II (not 
shown) or insulin (fig.3B). The same anti-calpain 
II or anti-calpastatin used in our experiments 
showed intense immunostaining in other tissues. 
4. DISCUSSION 
Here, we localized calpain I, a Ca’+-dependent 
protease, almost exclusively in the human en- 
docrine pancreas, especially in B-cells of islets, by 
immunostaining of consecutive tissue sections us- 
ing specific antibodies. No significant immuno- 
staining was obtained in the exocrine pancreas. 
The localization pattern is rather unexpected, since 
it is not the endocrine pancreas, but the exocrine 
pancreas that has long been known as a rich source 
of proteases. 
Judging from the intensity of immunostainings, 
it is obvious that the amount of calpain I, which re- 
quires only a micromolar level of Ca2+ for activa- 
tion, in islet B-cells far exceeds that of calpain II, 
which requires a millimolar level of Ca2+ for ac- 
tivation. The predominance of calpain I over cal- 
Fig.2. Immunohistochemical localization of calpain I and pancreatic hormones in a series of consecutive paraffin 
sections of human pancreas. A and F, stainings for calpain I; B and G, for insulin; C and H, for glucagon; D and I, 
for somatostatin; E and J, for pancreatic polypeptide. The islet in the upper panel contains few D-cells (D), whereas 
the islet in the lower panel contains few pp-cells (J). 
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Fig.3. Immunostaining pattern for calpain I after preabsorption of the anti-calpain I antibody with calpain I (A) a 
insulin (B). 
md 
pain II is a characteristic feature of islet B-cells, for 
most of the cells and tissues usually contain more 
calpain II than calpain I as has been described in 
several distribution studies, leaving erythrocytes 
and the submandibular gland as rare exceptions 
]161. 
Various cells and tissues are known to contain a 
specific proteinous inhibitor of calpain, namely 
calpastatin [1,161. Distribution studies showed that 
the inhibitory activity of calpastatin in various cells 
and tissues is usually significant enough for it to 
easily cope with enzymatic activities of endogenous 
calpains [1,16], and this gives another regulatory 
mechanism for the Ca2+-dependent proteolytic 
system in various cells and tissues. However, the 
amount of calpastatin in islet B-cells is shown to be 
remarkably low, which is another characteristic 
feature of islet B-cells. 
These data collectively indicate that the 
Ca2+-dependent proteolytic system in human pan- 
creatic B-cells can readily be activated functionally 
by only a small rise in the intracellular Ca2+ con- 
centration at the micromolar level, without any 
great interference by calpastatin. 
It is well known that Ca2+ plays an important 
role in the process of insulin secretion by B-cells 
(review [ 171). A significant influx of Ca2+ has been 
detected in the process of glucose-mediated insulin 
secretion [ 171. The presence of some Ca2+-binding 
proteins such as calmodulin [18] and vitamin D- 
dependent calcium-binding protein [19] in islet B- 
cells has been demonstrated and suggested to be 
implicated in the process of insulin secretion. Cal- 
pain may also be implicated in the process, though 
the precise role played by the enzyme remains 
unclear. 
Ca2+-dependent protein kinase (C-kinase) is 
reported to be activated during the course of 
glucose-induced insulin secretion by B-cells 
[20,21]. It is tempting to suggest that one of the 
physiological functions of calpain I in B-cells could 
be the activation of C-kinase, since it has already 
been demonstrated that calpain I has a strong abili- 
ty to activate C-kinase in rat brain [22]. However, 
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calpain is not the sole factor which can activate C- 
kinase; another mechanism proposed for the ac- 
tivation of C-kinase is mediated by phosphatidyl- 
inositol-specific phospholipase C [23]. Which 
mechanism plays the central role in the activation 
of C-kinase during the course of glucose-mediated 
secretion of insulin will be the subject of ongoing 
studies. 
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